drugset / Trial / NCT02627027

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers

NCT02627027

Phase 1 Completed 26 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/750 mg in healthy male volunteers.

Timeline

Start
2015-08
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.25 mg Oral
Subject Lobeglitazone Small molecule 0.5 mg Oral
Subject Metformin Small molecule 750 mg Oral
Subject Metformin Small molecule 1500 mg Oral